Nanocarriers assisted siRNA gene therapy for the management of cardiovascular disorders

Current Pharmaceutical Design

Volumn 21, Issue 30, 2015, Pages 4427-4440

  Maheshwari, Rahul ^a,b   Tekade, Muktika ^c   Sharma, Piyoosh A ^d   Tekade, Rakesh Kumar ^e  

^a Mahatma Jyoti Rao Phoole University   (India)

^b BM College of Pharmaceutical Education and Research   (India)

^c Technocrats Institute of Technology   (India)

^d Sri Aurobindo Institute of Technology   (India)

^e INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

Author keywords

Cardiovascular disorders; Myocardial infarction; RNAi; SiRNA

Indexed keywords

DENDRIMER; LIPOSOME; NANOCARRIER; PEPTIDE; SMALL INTERFERING RNA; DRUG CARRIER; NANOPARTICLE;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR GENE THERAPY; CARDIOVASCULAR MORTALITY; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; GENE TRANSFER; HUMAN; HYDROGEL; MICELLE; NANOTECHNOLOGY; NONHUMAN; PHYSICAL CHEMISTRY; PLASMA HALF LIFE; POSTTRANSCRIPTIONAL GENE SILENCING; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RNA INTERFERENCE; CARDIOVASCULAR DISEASES; CHEMISTRY; GENE THERAPY; GENETICS; PROCEDURES;

CARDIOVASCULAR DISEASES; DRUG CARRIERS; GENE SILENCING; GENETIC THERAPY; HUMANS; NANOPARTICLES; NANOTECHNOLOGY; RNA, SMALL INTERFERING;

EID: 84946051633     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161282130151007150300     Document Type: Article

References (190)

1. Perez-Pomares JM, Gonzalez-Rosa JM, Munoz-Chapuli R. Building the vertebrate heart: an evolutionary approach to cardiac development. Int J Dev Biol 2009; 53: 1427-43.
2. Wang HU, Chen ZF, Anderson DJ. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 1998; 93(5): 741-53.
3. Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell 2011; 146: 873-87.
4. Yancopoulos GD, Davis S, Gale NW, et al. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407(6801): 242-8.
5. Virágh S, Gittenberger-de Groot AC, Poelmann RE, et al.Early development of quail heart epicardium and associated vascular and glandular structures. Anat Embryol (Berl) 1993; 188(4): 381-93.
6. Zetter BR. The endothelial cells of large and small blood vessels. Diabetes 1981; 30(Suppl 2): 24-8.
7. Katare R, Riu F, Mitchell K, Gubernator M, et al.Transplantation of human pericyte progenitor cells improves the repair of infarcted heart through activation of an angiogenic program involving micro-RNA-132. Circ Res 2011; 109(8): 894-906.
8. Domenga V, Fardoux P, Lacombe P, et al.Notch3 is required for arterial identity and maturation of vascular smooth muscle cells. Genes Dev 2004; 18(22): 2730-5.
9. World Heart Federation. Different Heart Diseases, Available from: (http://www.world-heart-federation.org/cardiovascularhealth/ heart-disease/different-heart-diseases/)
10. Mackay JMG, Atlas of heart disease and stroke. World Health Organization (WHO): Geneva Press 2004.
11. Eckel RH, Krauss RM. American Heart Association call to action: obesity as a major risk factor for coronary heart disease. AHA Nutrition Committee. Circulation 1998; 97(21): 2099-100.
12. Pearson TA, Blair SN, Daniels SR, et al.AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 Update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. american heart association science advisory and coordinating committee. Circulation 2002; 106(3): 388-91.
13. Derby CA, Mohr BA, Goldstein I, et al.Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology 2000; 56(2): 302-6.
14. Trick WE, Scheckler WE, Tokars JI, et al.Modifiable risk factors associated with deep sternal site infection after coronary artery bypass grafting. J Thorac Cardiovasc Surg 2000; 119(1): 108-14.
15. Turner RC, Millns H, Neil HAW. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23) BMJ 1998; 316(7134): 823-828.
16. de Lorgeril M, Salen P, Martin JL, et al.Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999; 99(6): 779-85.
17. Yusuf S, Hawken S, Ounpuu S, et al.Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364(9438): 937-52.
18. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care 1979; 2(2): 120-6.
19. Schott JJ, Benson DW, Basson CT, et al.Congenital heart disease caused by mutations in the transcription factor NKX2-5. Science 1998; 281(5373): 108-11.
20. Schott JJ, Alshinawi C, Kyndt F, et al.Cardiac conduction defects associate with mutations in SCN5A. Nat Genet 1999; 23(1): 20-1.
21. Richards AA and Garg V. Genetics of congenital heart disease. Curr Cardiol Rev 2010; 6(2): 91–97.
22. Ranger AM, Grusby MJ, Hodge MR, et al.The transcription factor NF-ATc is essential for cardiac valve formation. Nature 1998; 392(6672): 186-90.
23. Pierpont ME, Basson CT, Benson DW Jr., et al.Genetic basis for congenital heart defects: current knowledge: a scientific statement from the american heart association congenital cardiac defects committee, council on cardiovascular disease in the young: endorsed by the american academy of pediatrics. Circulation 2007; 115(23): 3015-38.
24. van der Linde D, Konings EE, Slager MA, et al.Birth prevalence of congenital heart disease worldwide: a systematic review and metaanalysis. J Am Coll Cardiol 2011; 58: 2241-7.
25. Garg V, Kathiriya IS, Barnes R, et al.GATA4 mutations cause human congenital heart defects and reveal an interaction with TBX5. Nature 2003; 424(6947): 443-7.
26. Britz-Cunningham SH, Shah MM, Zuppan CW, et al.Mutations of the Connexin43 gap-junction gene in patients with heart malformations and defects of laterality. N Engl J Med 1995; 332(20): 1323-9.
27. Bruneau BG. The developmental genetics of congenital heart disease. Nature 2008; 451: 943-8.
28. Olson EN. Gene regulatory networks in the evolution and development of the heart. Science 2006; 313: 1922-7.
29. Olson EN, Schneider MD. Sizing up the heart: development redux in disease. Genes Dev 2003; 17: 1937-56.
30. Alwan A, Global Status Report on Noncommunicable Diseases 2010. World Health Organization (WHO): Geneva Press 2004.
31. Corella D, Ordovas JM. Aging and cardiovascular diseases: The role of gene-diet interactions. Ageing Res Rev 2014; 18: 53-73.
32. Huxley RR, Woodward M. Cigarette smoking as a risk factor for coronary heart disease in women compared with men: a systematic review and meta-analysis of prospective cohort studies. Lancet 2011; 378: 1297-305.
33. Volpe M, Erhardt LR, Williams B. Managing cardiovascular risk: the need for change. J Hum Hypertens 2008; 22: 154-7.
34. Charlson FJ, Stapelberg NJ, Baxter AJ, et al.Should global burden of disease estimates include depression as a risk factor for coronary heart disease? BMC Med 2011; 9: 47-52.
35. Coumbe AG, Marc RMD, Pritzker MD, et al.Cardiovascular risk and psoriasis: beyond the traditional risk factors. Am J Med 2014; 127: 12-8.
36. Antoniades C, Antonopoulos AS, Bendall JK, et al.Targeting redox signaling in the vascular wall: from basic science to clinical practice. Curr Pharm Des 2009; 15: 329-42.
37. Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet 2007; 8: 173-84.
38. Elbashir SM, Harborth J, Lendeckel W, et al.Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494-8.
39. Sijen T, Fleenor J, Simmer F, et al.On the role of RNA amplification in dsRNA-triggered gene silencing. Cell 2001; 107(4): 465-76.
40. Tiscornia G, Singer O, Ikawa M, et al.A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. Proc Natl Acad Sci USA 2003; 100(4): 1844-8.
41. Tang G. siRNA and miRNA: an insight into RISCs. Trends Biochem Sci 2005; 30: 106-14.
42. Lu PY, Woodle MC. Delivering small interfering RNA for novel therapeutics. Methods Mol Biol 2008; 437: 93-107.
43. Meister G, Tuschl T. Mechanisms of gene silencing by doublestranded RNA. Nature 2004; 431: 343-9.
44. Kesharwani P, Gajbhiye V, Jain NK. A review of nanocarriers for the delivery of small interfering RNA. Biomaterials 2012; 33(29): 7138-50.
45. Caplen NJ, Parrish S, Imani F, et al.Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc Natl Acad Sci USA 2001; 98(17): 9742-7.
46. Rosengren A, Hawken S, Ounpuu S, et al.Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364(9438): 953-62.
47. Hannon GJ. RNA interference. Nature 2002; 418: 244-51.
48. Fire A, Xu S, Montgomery MK et al.Potent and specific genetic interference by double-stranded RNA in Caenorhabditiselegans. Nature 1998; 391: 806-11.
49. Opalinska JB, Gewirtz AM. Nucleic-acid therapeutics: basic principles and recent applications. Nat Rev Drug Discov 2002; 1(7): 503-14.
50. Hovey BM, Ward JE, Soo Hoo P, et al.Preclinical development of siRNA therapeutics for AL amyloidosis. Gene Ther 2011; 18(12): 1150-6.
51. Shen Y. Advances in the development of siRNA-based therapeutics for cancer. IDrugs 2008; 11(8): 572-8.
52. Judge AD, Robbins M, Tavakoli I, et al.Confirming the RNAimediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest 2009; 119(3): 661-73.
53. Ozpolat B, Sood AK, Lopez-Berestein G. Nanomedicine based approaches for the delivery of siRNA in cancer. J Intern Med 2010; 267(1): 44-53.
54. Tong AW, Zhang YA, Nemunaitis J. Small interfering RNA for experimental cancer therapy. Curr Opin Mol Ther 2005; 7(2): 114-24.
55. Soutschek J, Akinc A, Bramlage B, et al.Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004; 432(7014): 173-8.
56. Qi X, Bao FS, Xie Z. Small RNA deep sequencing reveals role for Arabidopsis thaliana RNA-dependent RNA polymerases in viral siRNA biogenesis. PLoS One 2009; 4(3): e4971.
57. Lu R, Yigit E, Li WX, et al. An RIG-I-Like RNA helicase mediates antiviral RNAi downstream of viral siRNA biogenesis in Caenorhabditiselegans. PLoS Pathog 2009; 5(2): e1000286.
58. Taratula O, Garbuzenko O, Savla R, et al. Multifunctional nanomedicine platform for cancer specific delivery of siRNA by superparamagnetic iron oxide nanoparticles-dendrimer complexes. Curr Drug Deliv 2011; 8(1): 59-69.
59. Tokatlian T, Segura T. siRNA applications in nanomedicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2010; 2 (3): 305-15.
60. Jackson AL, Burchard J, Schelter J, et al.Widespread siRNA "offtarget" transcript silencing mediated by seed region sequence complementarity. RNA 2006; 12(7): 1179-87.
61. Jagla B, Aulner N, Kelly PD, et al.Sequence characteristics of functional siRNAs. RNA 2005; 11(6): 864-72.
62. Li YG, Zhang PP, Jiao KL, et al.Knockdown of microRNA-181 by lentivirus mediated siRNA expression vector decreases the arrhythmogenic effect of skeletal myoblast transplantation in rat with myocardial infarction. Microvasc Res 2009; 78(3): 393-404.
63. Newaz M, Ranganna K, Truong LD, et al.Effect of peroxisome proliferator-activated receptor-alpha siRNA on hypertension and renal injury in the rat following nitric oxide withdrawal and high salt diet. J Hypertens 2009; 27(11): 2223-31.
64. Gandhi NS, Tekade RK, Chougule MB. Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances. J Control Release 2014; 194: 238-56.
65. O'Toole AS, Miller S, Haines N, Comprehensive thermodynamic analysis of 3' double-nucleotide overhangs neighboring Watson-Crick terminal base pairs. Nucleic Acids Res 2006; 34(11): 3338-44.
66. Grimson A, Farh KK, Johnston WK, et al.MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell 2007; 27(1): 91-105.
67. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136(2): 215-33.
68. Long D, Lee R, Williams P, et al.Potent effect of target structure on microRNA function. Nat Struct Mol Biol 2007; 14(4): 287-94.
69. Varambally S, Cao Q, Mani RS, et al.Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008; 322(5908): 1695-9.
70. Selaru FM, Olaru AV, Kan T, et al.MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology 2009; 49(5): 1595-601.
71. Chen Y, Zhu X, Zhang X, et al.Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther 2010; 18(9): 1650-6.
72. Zhang Y, Wang Z, Gemeinhart RA. Progress in microRNA delivery. J Control Release 2013; 172(3): 962-74.
73. Dong H, Ding L, Yan F, et al.The use of polyethylenimine-grafted graphene nanoribbon for cellular delivery of locked nucleic acid modified molecular beacon for recognition of microRNA. Biomaterials 2011; 32(15): 3875-82.
74. Trang P, Wiggins JF, Daige CL, Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther 2011; 19(6): 1116-22.
75. Dorsett Y, Tuschl T. siRNAs: applications in functional genomics and potential as therapeutics. Nat Rev Drug Discov 2004; 3(4): 318-29.
76. Morris KV. Therapeutic potential of siRNA-mediated transcriptional gene silencing. Biotechniques 2006; Suppl: 7-13.
77. Youngren SR, Tekade RK, Gustilo B, et al.STAT6 siRNA matrixloaded gelatin nanocarriers: formulation, characterization, and ex vivo proof of concept using adenocarcinoma cells. Biomed Res Int 2013; 2013: 858946.
78. Arnold AS, Tang YL, Qian K, et al.Specific β1-adrenergic receptor silencing with small interfering RNA lowers high blood pressure and improves cardiac function in myocardial ischemia. J Hypertens 2007; 25: 197-205.
79. Gewirtz AM. On future’s doorstep: RNA interference and the pharmacopeia of tomorrow. J Clin Invest 2007; 117(12): 3612-4.
80. Zhang Y, Cristofaro1 P, Silbermann R, et al.Engineering mucosal RNA interference in vivo. Mol Ther 2006; 14: 336-42.
81. van de Water FM, Boerman OC, Wouterse AC, et al.Intravenousely administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. Drug Metab Dispos 2006; 34: 1393-7.
82. Kleinman ME, Yamada K, Takeda A, et al.Sequence-and target independent angiogenesis suppression by siRNA via TLR3. Nature 2008; 452: 591-7.
83. DiFiglia M, Sena-Esteves M, Chase K, et al.Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci USA 2007; 104: 17204-9.
84. Harper SQ, Staber PD, He X, et al.RNA interference improves motor and neuropathological abnormalities in a Huntington’s disease mouse model. Proc Natl Acad Sci USA 2005; 102: 5820-5.
85. Rodriguez-Lebron E, Paulson HL. Allele-specific RNA interference for neurological disease. Gene Ther 2006; 13: 576-81.
86. Rohl T, Kurreck J. RNA interference in pain research. J Neurochem 2006; 99 (2): 371-80.
87. Christoph T, Grunweller A, Mika J, et al.Silencing of vanilloid receptor TRPV1 by RNAi reduces neuropathic and visceral pain in vivo. Biochem Bioph Res Commun 2006; 350(1): 238-43.
88. Hickerson RP, Smith FJD, McLean WHI, et al.SiRNA-mediated selective inhibition of mutant keratin mRNAs responsible for the skin disorder pachyonychia congenita. Ann NY Acad Sci 2006; 1082: 56-61.
89. Xia H, Mao Q, Eliason SL, et al.RNAi suppresses polyglutamineinduced neurodegeneration in a model of spinocerebellar ataxia. Nat Med 2004; 10: 816-20.
90. Ding H, Schwarz DS, Keene A, et al.Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis. Aging Cell 2003; 2(4): 209-17.
91. Tillya G, Chapuis J, Vilette D, et al.Efficient and specific downregulation of prion protein expression by RNAi. Biochem Biophys Res Comm 2003; 305(3): 548-51.
92. Kao SC, Krichevsky AM, Kosik KS, et al.BACE1 suppression by RNA interference in primary cortical neurons. J Biol Chem 2004; 279: 1942-9.
93. Bumcrot D, Manoharan M, Koteliansky V, et al.RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2006; 2: 711-9.
94. Jackson AL, Linsley PS. Noise amidst the silence: off-target effects of siRNAs? Trends Genet 2004; 20(11): 521-4.
95. Jackson AL, Linsley PS. Recognizing and avoiding siRNA offtarget effects for target identification and therapeutic application. Nat Rev Drug Discov 2010; 9(1): 57-67.
96. Stormo GD. An Overview of RNA Structure Prediction and Applications to RNA Gene Prediction and RNAi Design, Current Protocols in Bioinformatics, Wiley Online Library 2006; 13: 12.1: 12.1.1–12.1.3.
97. Klingelhoefer JW, Moutsianas L, Holmes C, Approximate Bayesian feature selection on a large meta-dataset offers novel insights on factors that effect siRNA potency. Bioinformatics 2009; 25(13): 1594-601.
98. Luo Q, Kang Q, Song WX, et al.Selection and validation of optimal siRNA target sites for RNAi-mediated gene silencing. Gene Volume 2007; 395: 160-9.
99. Zheng D, Giljohann DA, Chen DL, et al. Topical delivery of siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation. Proc Natl Acad Sci 109(30): 11975-80.
100. Xu J, Zeng C, Chu W, et al.Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site. Nat Commun 2011; 2: 380.
101. Guo P, Coban O, Snead NM, et al.Engineering RNA for Targeted siRNA Delivery and Medical Application. Adv Drug Deliver Rev 2010; 62(6): 650-66.
102. Tran DQ, Andersson J, Wang R, et al.GARP (LRRC32) is essential for the surface expression of latent TGF-_ on platelets and activated FOXP3+ regulatory T cells. Proc Natl Acad Sci 2009; 106(32): 13445-50.
103. Schroeder A, Levins CG, Cortez C, et al.Lipid-based nanotherapeutics for siRNA delivery. J Intern Med 2010; 267(1): 9-21.
104. Ishida H, Ray R, Ray P. Sulfur mustard downregulates iNOS expression to inhibit wound healing in a human keratinocyte model. J Dermatol Sci 2008; 49(3): 207-16.
105. Judge AD, Bola G, Lee ACH, et al.Design of Noninflammatory Synthetic siRNA Mediating Potent Gene Silencing in vivo. Mol Ther 2006; 13: 494-505.
106. Persengiev SP, Zhu X, Green MR. Nonspecific, concentrationdependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs). RNA 2004; 10: 12-8.
107. Bridge AJ, Pebernard S, Ducraux A, et al.Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet 2003; 34: 263-4.
108. Sledz CA, Holko M, de Veer MJ, et al.Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 2003; 5: 834-9.
109. Lorenz C, Hadwiger P, John M, et al.Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg Med Chem Lett 2004; 14(19) 4975-7.
110. Lu PY, Xie F, Woodle MC, et al.In vivo application of RNA interference: from functional genomics to therapeutics. Adv Genet 2005; 54: 115-42.
111. Castanotto D, Rossi JJ. The promises and pitfalls of RNAinterference-based therapeutics. Nature 2009; 457: 426-33.
112. Raemdonck K, Vandenbroucke RE, Demeester J, et al.Maintaining the silence: reflections on long-term RNAi. Drug Discov Today 2008; 13: 917-31.
113. Haupenthal J, Baehr C, Kiermayer S, et al.Inhibition of RNAse A family enzymes prevents degradation and loss of silencing activity of siRNAs in serum. Biochem Pharmacol 2006; 71(5); 702-10.
114. Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. Nat Rev Mol Cell Bio 2009; 10: 126-39.
115. Dreyer JL. Lentiviral Vector-Mediated Gene Transfer and RNA silencing technology in neuronal dysfunctions. Methods Mol Biol 2010; 614: 3-35.
116. Couto LB, High KA. Viral vector-mediated RNA interference. Curr Opin Pharmacol 2010; 10(5): 534-42.
117. Sliva K, Schnierle BS. Selective gene silencing by viral delivery of short hairpin RNA. Virol J 2010; 7: 248.
118. Lei ZN, Zhang LM, Sun FY. Beta-catenin siRNA inhibits ischemiainduced striatal neurogenesis in adult rat brain following a transient middle cerebral artery occlusion. Neurosci Lett 2008; 435(2): 108-12.
119. Molitoris BA, Dagher PC, Sandoval RM, et al.siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. J Am Soc Nephrol 2009; 20(8): 1754-64.
120. Reich SJ, Fosnot J, Kuroki A, et al.Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 2003; 9: 210-6.
121. Hu CJ, Iyer S, Sataur A, et al.Differential regulation of the transcriptional activities of hypoxia-inducible factor 1 alpha (HIF-1α) and HIF-2α in stem cells. Mol Cell Biol 2006; 26(9): 3514-26.
122. Tekade RK, Dutta T, Tyagi A, et al.Surface-engineered dendrimers for dual drug delivery: a receptor up-regulation and enhanced cancer targeting strategy. J Drug Target 2008; 16(10): 758-72.
123. Kesharwani P, Tekade RK, Gajbhiye V, et al.Cancer targeting potential of some ligand-anchored poly(propylene imine) dendrimers: a comparison. Nanomedicine 2011; 7(3): 295-304.
124. Maheshwari RGS, Thakur S, Singhal S, et al.Chitosan encrusted nonionic surfactant based vesicular formulation for topical administration of ofloxacin. Sci Adv Mater 2015; 7: 1163-76.
125. Vodovozova EL, Kuznetsova NR, Kadykov, VA, et al.Liposomes as nanocarriers of lipid-conjugated antitumor drugs melphalan and methotrexate. Nanotechnol Russia 2008; 3(3-4): 228-39.
126. Sawant RR, Torchilin VP. Liposomes as ‘smart’ pharmaceutical nanocarriers. Soft Matter 2010; 6: 4026-44.
127. Bybee KA, Kara T, Prasad A, et al.Systematic review: transient left ventricular apical ballooning: a syndrome that mimics STsegment elevation myocardial infarction. Ann Intern Med 2004; 141(11): 858-65.
128. Haywood LJ. Treatment of myocardial infarction: a review. J Natl Med Assoc 1988; 80(4): 459-461.
129. Gill C, Mestril R, Samali A. Losing heart: the role of apoptosis in heart disease-a novel therapeutic target? FASEB J 2002; 16(2): 135-46.
130. Kannan K, Jain SK. Oxidative stress and apoptosis. Pathophysiology 2000; 7(3): 153-163.
131. Kumar D, Jugdutt BI. Apoptosis and oxidants in the heart. J Lab Clin Med 2003; 142(5): 288-97.
132. MacLellan WR, Schneider MD. Death by design. Programmed cell death in cardiovascular biology and disease. Circ Res 1997; 81(2): 137-44.
133. Kim YD, Park KG, Lee YS, Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. Diabetes 2008; 57(2): 306-14.
134. Kim D, Hong J, Moon HH, et al.Anti-apoptotic cardioprotective effects of SHP-1 gene silencing against ischemia-reperfusion injury: use of deoxycholic acid-modified low molecular weight polyethyleneimine as a cardiac siRNA-carrier. J Control Release 2013; 168(2): 125-34.
135. Hong J, Ku SH, Lee MS, et al.Cardiac RNAi therapy using RAGE siRNA/deoxycholic acid-modified polyethylenimine complexes for myocardial infarction. Biomaterials 2014; 35(26): 7562-73.
136. Somasuntharam I, Boopathy AV, Khan RS, et al.Delivery of Nox2-NADPH oxidase siRNA with polyketal nanoparticles for improving cardiac function following myocardial infarction. Biomaterials 2013; 34(31): 7790-8.
137. Hagenmueller M, Malekar P, Fieger C, et al.Depletion of mammalian target of rapamycin (mTOR) via siRNA mediated knockdown leads to stabilization of b-catenin and elicits distinct features of cardiomyocyte hypertrophy. FEBS Lett 2010; 584: 74-80.
138. Liu J, Gu C, Cabigas EB, et al.Functionalized dendrimer-based delivery of angiotensin type 1 receptor siRNA for preserving cardiac function following infarction. Biomaterials 2013; 34(14): 3729-36.
139. Li H, Zheng X, Koren V, et al.Highly efficient delivery of siRNA to a heart transplant model by a novel cell penetrating peptidedsRNA binding domain. Int J Pharm 2014; 469(1): 206-13.
140. Watanabe K, Arumugam S, Sreedhar R, et al. Small interfering RNA therapy against carbohydrate sulfotransferase 15 inhibits cardiac remodeling in rats with dilated cardiomyopathy. Cell Signal 2015; S0898-6568(15)00091-1.
141. Hu H, Xuan Y, Wang Y, et al.Targeted NGF siRNA delivery attenuates sympathetic nerve sprouting and deteriorates cardiac dysfunction in rats with myocardial infarction. PLoS One 2014; 9(4): e95106.
142. Wang K, Long B, Jiao JQ, et al.miR-484 regulates mitochondrial network through targeting Fis1. Nat Commun 2012; 3: 781.
143. Collins RG, Velji R, Guevara NV, et al.P-Selectin or intercellular adhesion molecule (ICAM)-1 deficiency substantially protects against atherosclerosis in apolipoprotein E-deficient mice. J Exp Med 2000; 191(1): 189-94.
144. Gu J, Fan Y, Liu X, et al.SENP1 protects against myocardial ischaemia/reperfusion injury via a HIF1_-dependent pathway. Cardiovasc Res 2014; 104(1): 83-92.
145. Olearczyk J, Gao S, Eybye M, et al.Targeting of hepatic angiotensinogen using chemically modified siRNAs results in significant and sustained blood pressure lowering in a rat model of hypertension. Hypertens Res 2014; 37(5): 405-12.
146. Petersen EJ, Miyoshi T, Yuan Z, et al.siRNA silencing reveals role of vascular cell adhesion molecule-1 in vascular smooth muscle cell migration. Atherosclerosis 2008; 198(2): 301-6.
147. Pluvinet R, Pétriz J, Torras J, et al.RNAi-mediated silencing of CD40 prevents leukocyte adhesion on CD154-activated endothelial cells. Blood 2004; 104(12): 3642-6.
148. San Juan A, Bala M, Hlawaty H, et al.Development of a functionalized polymer for stent coating in the arterial delivery of small interfering RNA. Biomacromolecules 2009; 10(11): 3074-80.
149. Arnold AS, Tang YL, Qian K, et al.Specific beta1-adrenergic receptor silencing with small interfering RNA lowers high blood pressure and improves cardiac function in myocardial ischemia. J Hypertens 2007; 25(1): 197-205.
150. Sun B, Kintsurashvili E, Ona D, et al.Inhibition of the alpha(1D)-adrenergic receptor gene by RNA interference (RNAi) in rat vascular smooth muscle cells and its effects on other adrenergic receptors. Vascul Pharmacol 2007; 46(5): 367-72.
151. Gajbhiye V, Vijayaraj Kumar P, Tekade RK, Jain NK. PEGylated PPI dendritic architectures for sustained delivery of H2 receptor antagonist. Eur J Med Chem 2009; 44: 1155-66.
152. Kurmi BD, Kayat J, Gajbhiye V, Tekade RK, Jain NK. Micro-and nanocarrier-mediated lung targeting. Expert Opin Drug Deliv 2010; 7: 781-94.
153. Jain S, Kesharwani P, Tekade RK, Jain NK. One platform comparison of solubilization potential of dendrimer with some solubilizing agents. Drug Dev Ind Pharm 2014.
154. Dwivedi P, Tekade RK, Jain NK. Nanoparticulate Carrier Mediated Intranasal Delivery of Insulin for the Restoration of Memory Signaling in Alzheimer’s Disease. Curr Nanosci 2013; 9: 46-55.
155. Kesharwani P, Tekade RK, Jain NK. Generation dependent safety and efficacy of folic Acid conjugated dendrimer based anticancer drug formulations. Pharm Res 2015; 32: 1438-50.
156. Chopdey PK, Tekade RK, Mehra NK, Mody N, Jain NK. Glycyrrhizin conjugated dendrimer and multi-walled carbon nanotubes for liver specific delivery of doxorubicin. J Nanosci Nanotechnol 2015; 15: 1088-1100.
157. Tekade RK, Chougule MB. Formulation development and evaluation of hybrid nanocarrier for cancer therapy: taguchi orthogonal array based design. BioMed Research International 2013.
158. Kesharwani P, Tekade RK, Jain NK. Generation dependent cancer targeting potential of poly(propyleneimine) dendrimer. Biomaterials 2014; 35: 5539-48.
159. Kesharwani P, Tekade RK, Jain NK. Formulation development and in vitro-in vivo assessment of the fourth-generation PPI dendrimer as a cancer-targeting vector. Nanomedicine (Lond) 2014; 9: 2291-308.
160. Maheshwari RGS, Tekade RK, Dharvekar G, Jain D. K. Ethosomes and ultradeformable liposomes for transdermal delivery of clotrimazole: a comparative assessment. Saudi Pharm J 2012; 20: 161–170.
161. Tekade RK, Dutta T, Gajbhiye V, Jain NK. Exploring dendrimer towards dual drug delivery: pH responsive simultaneous drugrelease kinetics. J Microencapsul 2009; 26: 287-96.
162. Kesharwani P, Gajbhiye V, Tekade RK, Jain NK. Evaluation of dendrimer safety and efficacy through cell line studies. Curr Drug Targets 2011; 12: 1478-97.
163. Dhakad RS, Tekade RK, Jain NK. Cancer targeting potential of folate targeted nanocarrier under comparative influence of tretinoin and dexamethasone. Curr Drug Deliv 2013; 10: 477-91.
164. Tekade RK, Kumar PV, Jain NK. Dendrimers in oncology: an expanding horizon. Chem Rev 2009; 109: 49-87.
165. Thakur S, TRK P, Jain N.K. The effect of polyethylene glycol spacer chain length on the tumor targeting potential of folate modified PPI dendrimers. J Nanoparticle Res 2013; 15: 1625.
166. Tekade RK, Youngren-Ortiz SR, Yang H, Haware R, Chougule MB. Designing hybrid onconase nanocarriers for mesothelioma therapy: a Taguchi orthogonal array and multivariate component driven analysis. Mol Pharm 2014; 11: 3671-83.
167. Tekade RK, Tekade M, Kumar M, Chauhan AS. Dendrimerstabilized smart-nanoparticle (DSSN) platform for targeted delivery of hydrophobic antitumor therapeutics. Pharm Res 2015; 32: 910-28.
168. Jain NK, Tekade RK. Dendrimers for Enhanced Drug Solubilization. Drug Delivery Strategies for Poorly Water-Soluble Drugs. USA: John Wiley & Sons Ltd 2013; pp. 373-409.
169. Gajbhiye V, Palanirajan VK, Tekade RK, Jain NK. Dendrimers as therapeutic agents: a systematic review. J Pharm Pharmacol 2009; 61: 989-1003.
170. Mody N, Tekade RK, Mehra NK, Chopdey P, Jain NK. Dendrimer, liposomes, carbon nanotubes and PLGA nanoparticles: one platform assessment of drug delivery potential. AAPS Pharm Sci Tech 2014; 15: 388-99.
171. Kesharwani P, Tekade RK, Jain NK. Dendrimer generational nomenclature: the need to harmonize. Drug Discov Today 2015. pii: S1359-6446(14) 00486-3
172. Prajapati RN, Tekade RK, Gupta U, Gajbhiye V, Jain NK. Dendimer-mediated solubilization, formulation development and in vitroin vivo assessment of piroxicam. Mol Pharm 2009; 6: 940-50.
173. Kayat J, Gajbhiye V, Tekade RK, Jain NK. Pulmonary toxicity of carbon nanotubes: a systematic report. Nanomedicine 2011; 7: 40-9.
174. Maheshwari RGS, Thakur S, Singhal S, Patel RP, Tekade M, Tekade RK. Chitosan Encrusted Nonionic Surfactant Based Vesicular Formulation for Topical Administration of Ofloxacin. Sci Adv Mater 2015; 7: 1163-1176.
175. Rosenquist TH, Chaudoin T, Finnell RH, et al, High-affinity folate receptor in cardiac neural crest migration: a gene knockdown model using siRNA. Dev Dyn 2010; 239(4): 1136-44.
176. Blaschke F, Bruemmer D, Yin F, et al.C-reactive protein induces apoptosis in human coronary vascular smooth muscle cells. Circulation 2004; 110: 579–87
177. Hamar P, Song E, Kokeny G, et al.Small interfering RNA targeting Fas protects mice against renal ischemia-reperfusion injury. Proc Natl Acad Sci USA 2004; 101: 14883–8.
178. Wan X, Fan L, Hu B, et al.Small interfering RNA targeting IKKβ prevents renal ischemia-reperfusion injury in rats. Am J Physiol Renal Physiol 2011; 300(4): F857-63.
179. Feng B, Chen G, Zheng X, et al.Small interfering RNA targeting RelB protects against renal ischemia-reperfusion injury. Transplantation 2009; 87(9): 1283-9.
180. Gong X, Han B, Zou Y, et al.Attenuation of experimental autoimmune myocarditis by si-RNA mediated CD40 silencing. Int Heart J 2014; 55(6): 539-45.
181. Cooper LT Jr., Fairweather D. Nano-scale treatment for a macroscale disease: nanoparticle-delivered siRNAsilences CCR2 and treats myocarditis.Eur Heart J 2014; pii: ehu302.
182. Leuschner F, Courties G, Dutta P, et al. Silencing of CCR2 in myocarditis. Eur Heart J 2014 Jun 20. pii: ehu225.
183. Bi D, Nishimura J, Niiro N, et al.Contractile properties of the cultured vascular smooth muscle cells. The crucial role played by RhoA in the regulation of contractility. Circ Res 2005; 96: 890-7.
184. Hong J, Ku SH, Lee MS, et al.Cardiac RNAi therapy using RAGE siRNA/deoxycholic acid-modified polyethylenimine complexes for myocardial infarction. Biomaterials 2014; 35(26): 7562-73.
185. Kim D, Lee D, Jang YL, et al.Facial amphipathic deoxycholic acid-modified polyethyleneimine for efficient MMP-2 siRNA de livery in vascular smooth muscle cells. Eur J Pharm Biopharm 2012; 81(1): 14-23.
186. Nam HY, Kim J, Kim S, et al.Cell penetrating peptide conjugated bioreducible polymer for siRNA delivery. Biomaterials 2011; 32(22): 5213-22.
187. Kim SH, Jeong JH, Ou M, et al.Cardiomyocyte-targeted siRNA delivery by prostaglandin E(2)-Fas siRNA polyplexes formulated with reducible poly(amido amine) for preventing cardiomyocyte apoptosis. Biomaterials 2008; 29(33): 4439-46.
188. Nam HY, McGinn A, Kim PH, et al.Primary cardiomyocytetargeted bioreducible polymer for efficient gene delivery to the myocardium. Biomaterials 2010; 31(31): 8081-7.
189. Kowalski PS, Zwiers PJ, Morselt HW, et al.Anti-VCAM-1 SAINT-O-Somes enable endothelial-specific delivery of siRNA and downregulation of inflammatory genes in activated endothelium in vivo. J Control Release 2014; 176: 64-75.
190. Betigeri S, Zhang M, Garbuzenko O, et al.Non-viral systemic delivery of siRNA or antisense oligonucleotides targeted to Jun Nterminal kinase 1 prevents cellular hypoxic damage. Drug Deliv Transl Res 2011; 1(1): 13-24.